Abstract. Gastric cancer (GC) is among the most aggressive types of cancer and is the second leading cause of cancer-associated mortality worldwide. The specific role of deregulated expression/activity of histone methyltransferases (HMTs) in GC is poorly understood. The present study aimed to explore the possible oncogenic role of euchromatic histone lysine methyltransferase 1 (EHMT1) in gastric carcinogenesis. It was identified that EHMT1 was highly expressed in GC tissues compared with that in adjacent non-tumor tissues, and that EHMT1 expression levels were significantly associated with tumor stage and lymph node metastasis. Through knockdown of EHMT1 in the BGC-803 cell line, EHMT1 was demonstrated to promote a malignant phenotype, and to increase the wound healing, migration and invasion abilities of GC cells. Corresponding to these in vitro results, knockdown of EHMT1 also inhibited the peritoneal metastasis of GC cells in vivo. Furthermore, EHMT1 also regulated the expression of the epithelial-mesenchymal transition marker E-cadherin in vitro and in vivo. These results indicate that EHMT1 is upregulated in GC and serves an oncogenic role in GC development by regulating E-cadherin expression.
Introduction
Gastric cancer (GC), is among the most common types of cancer in Asia (1). The 5-year survival rate of patients with GC treated at an early stage is 90-95%. However, if GC develops to a late stage, the survival rate is significantly decreased (2) . Despite advances in the treatment of GC, a considerable number of patients remain with local recurrence or distant metastasis, and the underlying molecular mechanism of GC metastasis remains unclear (3) . Therefore, investigation of the regulatory mechanisms underlying the activation of GC cell metastasis is required for the effective diagnosis and treatment of GC.
Deregulation of epigenetic mechanisms contributes to GC development and progression, including acetylation, methylation, phosphorylation and ubiquitination (4) . Histone methylation has attracted increasing attention due to its participation in the process of heterochromatin formation, gene imprinting, X chromosome inactivation and gene transcriptional regulation (5, 6) . Histone methyltransferases (HMTs) are a class of catalytic 1-3 ethyl group transfer to histone lysine or arginine, and are classified into histone lysine methyltransferases (HKMTs) and histone arginine methyltransferases (7) . HKMTs can be further classified into 2 subgroups: SET domain and non-SET domain (8) . Aberrant HMT expression has been identified in GC, and has been demonstrated to contribute to GC metastasis and development by promoting oncogene expression or inhibiting the expression of tumor suppressor genes. For example, depletion of EHMT2 inhibits cell growth and induces apoptosis in GC, indicating therapeutic potential in GC (9) . High expression of SET domain containing (lysine methyltransferase) 8 (SET8) was associated with a shortened survival time in patients with GC, and the level of SET8 expression was identified as an independent predictor of GC outcome (10) . Enhancer of zeste2 polycomb repressive complex 2 subunit can mediate the inhibition of S100A4 on E-cadherin, and regulate the proliferation and migration of GC cells (11) . Abnormal EHMT1 expression in cancer tissues, including esophageal squamous cell cancer (12) and breast cancer (13) , suggests that EHMT1 functions in tumor pathogenesis and progression. However, whether EHMT1 serves a role in GC development remains unknown. The present study aimed to elucidate the role of EHMT1 deregulation in GC carcinogenesis, to characterize its putative oncogenic role and its potential clinical impact.
Materials and methods

Tissues.
The clinical research protocol of the present study was approved by the Ethical Committee of Shanghai East Hospital Euchromatic histone lysine methyltransferase 1 regulates cancer development in human gastric cancer by regulating E-cadherin (Shanghai, China) . GC tissues and matched non-tumor tissues were obtained from 97 patients who underwent curative surgery between March 2011 and September 2016 at the Department of Surgery, Shanghai East Hospital. None of the patients had received chemotherapy prior to surgery. Written informed consent was obtained from all participants. All tissue samples were immediately snap-frozen in liquid nitrogen or formalin-fixed (4% at 4˚C for 24 h) and paraffin-embedded.
Cell culture. The immortalized normal gastric epithelial cell line, GES-1, and the GC cell lines, BGC-803, AGS, KATO III and NCI-N87 (all cells were purchased from the library of the Chinese Academy of Sciences, Shanghai, China), were used in the present study. All cells were cultured in RPMI-1640 medium (Gibco; Thermo Fisher Scientific, Inc., Waltham, MA, USA) containing 10% fetal calf serum (Gibco; Thermo Fisher Scientific, Inc.), 100 µg/ml streptomycin and 100 U/ml penicillin at 37˚C in a humidified incubator containing 5% CO 2 .
Xenograft model. All animal experiments were approved by the Experimental Animal Ethics Committee of Shanghai East Hospital and performed according to the Guide for the Institutional Animal Care and Use Committee of Shanghai Tongji University (Shanghai China). Specific pathogen-free grade, male, four-week-old, 10-12 g weight male BALB/c nude mice were purchased from the Institute of Zoology, Chinese Academy of Sciences (Beijing, China). Animals were housed in cages with wood chip beddings in a temperature-controlled room (20-22˚C) with a 12-h light-dark cycle and 45-55% relative humidity, and were permitted free access to food and drinking water. In order to study the effect of EHMT1 on abdominal metastasis of gastric cancer and the expression of E-cadherin in the subcutaneous transplantation tumor, the mice were divided into 2 equal groups (five nude mice in each group), and subcutaneously (6x10 5 cells) or abdominally (2x10 6 cells) injected with either BGC-803/NC or BGC-803/sh1-EHMT1 cells. All mice were sacrificed after 30 days. Subcutaneous tumor grafts were removed, fixed in 4% formalin for 24 h in 4˚C to obtain 5-µm thick paraffin-embedded sections and analyzed by immunohistochemistry, and peritoneal metastasis nodules were counted and further analyzed. In the process, if the mice showed signs of cachexia or excessive ascites affecting their diet and activity, the experiment was promptly terminated.
Reverse transcription-quantitative polymerase chain reaction (RT-qPCR). Total RNA from GC tissues and cell lines were extracted using TRIzol (Thermo Fisher Scientific, Inc.), according to the manufacturer's protocol. cDNA was synthesized from 1 µg RNA using a reverse transcription kit (Promega Corporation, Madison, WI, USA), according to the manufacturer's protocols. RT-qPCR was performed using SYBR-Green PCR Master mix (Applied Biosystems; Thermo Fisher Scientific, Inc.), according to the manufacturer's instructions. GAPDH was used as an internal control. The PCR primers were as follows: EHMT1 forward, 5'-CAT GCA GCC AGT AAA GAT CCC-3', and reverse, 5'-CTG CTG TCG TCC AAA GTC AG-3'; and GAPDH forward, 5'-TTG GCA TCG TTG AGG GTC T-3' and reverse, 5'-CAG TGG GAA CAC GGA AAG C-3'. PCR reactions were performed with an initial denaturation at 95˚C for 5 min, followed by 30 cycles of 95˚C for 30 sec, 57˚C for 30 sec and 72˚C for 30 sec, with a final extension at 72˚C for 10 min. Gene expression was quantified using the 2 -ΔΔCq method (14) .
Immunohistochemistry (IHC).
Sections of a 5-µm thickness were sliced from the paraffin-embedded tissues of the mice or patients, and deparaffinized (100% xylene) and rehydrated in an ethanol series (100-50%). The sections were then treated in 0.01 mol/l citrate buffer (pH 6.0) for antigen retrieval. Plasmid construction and transfection. EHMT1 short hairpin RNAs (shRNAs) and negative control (NC) were obtained from OBIO (Shanghai, China). EHMT1 sh1RNA (targeting sequence, 5'-CGA GTC AAT AAC GCC AGC TAT-3'), sh2RNA (targeting sequence, 5'-CCT CGG TTC TGA GTC GTA TAA-3') or NC (targeting sequence, 5'-TTC TCC GAA CGT GTC ACG T-3') were cloned into G418 plasmids (Gibco; Thermo Fisher Scientific, Inc.). The plasmid products were then transfected separately into BGC-803 cells (6x10 4 cells/well) at 1,500 µg/ml using Lipofectamine 2000 (Thermo Fisher Scientific, Inc.), according to the manufacturer's protocol. A total of one month later following transfection, stably transfected cells were detected using RT-qPCR and western blotting.
Wound healing assay. BGC-803/sh1, BGC-803/sh2 cells and NC cells were cultured as a monolayer to 100% confluence in 6-well plates. The cells were then scratched with a sterile pipette tip. The plates were washed with PBS to remove the cellular debris, and then cultured in RPMI-1640 serum-free medium (Gibco; Thermo Fisher Scientific, Inc.). The extent of wound healing was observed at 0 and 48 h under an inverted phase contrast microscope.
Migration and invasion assays. The cell migration and invasion abilities were measured using a 24-well Transwell chamber with 8-µm pore inserts (Corning Inc., Corning, NY, USA). For the migration assay, 1.0x10 5 cells in 200 µl RPMI-1640 serumfree medium (Gibco; Thermo Fisher Scientific, Inc.) were placed in the upper chamber, whereas 600 µl media with 10% FBS was placed in the lower chamber. After 24 h, cells remaining on the upper side of inserts were gently scraped off and cells on the lower surface were fixed in 100% methanol and stained with 0.5% crystal violet (37˚C for 30 min). The invasion assay was performed according to the same protocol as the migration assay; however, the upper chamber was pre-coated with Matrigel. For the two assays, the stained cells were counted in 5 randomly selected fields under an inverted light microscope.
Statistical analysis.
The association between EHMT1 expression and clinicopathological characteristics was analyzed using Pearson's χ 2 test. The differences between 2 groups were analyzed using Student's t-test, and the differences between ≥3 groups were analyzed using one-way analysis of variance with Bonferroni's post-hoc test. All statistical analyses were performed using SPSS 18.0 software (SPSS Inc., Chicago, IL, USA). P<0.05 was considered to indicate a statistically significant difference.
Results
EHMT1 is overexpressed in GC tissues and is associated with tumor stage and lymph node metastasis. RT-qPCR was
performed to analyze mRNA expression of EHMT1 in GC tumor tissues and matched non-tumor tissues. The mRNA level of EHMT1 in GC tissues was significantly increased compared with that of adjacent non-tumor tissues (P<0.01; Fig. 1A) . The protein expression level of EHMT1 in gastric tissues was analyzed by IHC, revealing increased EHMT1 staining in GC tissues compared with that in non-tumor tissues (Fig. 1B-D) . The association between EHMT1 protein expression and the clinicopathological characteristics of 97 patients with GC are presented in Table I . χ 2 analysis suggested that high expression of EHMT1 in GC was significantly associated with tumor stage (P=0.033) and lymph node metastasis (P=0.003). However, there was no statistically significant association between EHMT1 expression and other clinicopathological features, including sex, age and tumor size.
Construction of stable EHMT1-knockdown GC cell lines.
EHMT1 expression was investigated in the immortalized gastric epithelial cell line, GES-1, and in a series of GC cell lines, including BGC-803, NCI-N87, AGS and KATO-III. Among these cell lines, BGC-803, NCI-N87, AGS and KATO-III exhibited increased EHMT1 expression compared with GES-1 (P<0.01; Fig. 2A and B) . To further explore the functions of EHMT1 in GC cells, knockdown of EHMT1 expression was performed in BGC-803 cell lines, and experimentally validated (P<0.01; Fig. 2C and D) .
EHMT1 promotes wound healing, migration and invasion of GC cells.
Wound healing assays were performed to investigate the effect of EHMT1 on GC cell motility. It was observed that the distance between wound edges in the BGC-803/sh1-EHMT1 and BGC-803/sh2-EHMT1 cells was large compared with that in the control cells (P<0.01; Fig. 3A and B) .
The effect of EHMT1 on GC cell migration and invasion, which are key determinants of malignant progression and metastasis, was also assessed using Transwell assays. After 24 h of incubation, cells were counted under an inverted microscope. As illustrated in Fig. 3C and D, the number of cells that migrated into the lower chamber was significantly lower in BGC-803/sh1-EHMT1 and BGC-803/sh2-EHMT1 cells compared with that in BGC-803/NC cells in the migration and invasion assays (all P<0.01).
EHMT1 expression promotes peritoneal metastasis of GC cells.
Based on the aforementioned in vitro results, the in vivo function of overexpressed EHMT1 was investigated by abdominally injecting BGC-803/sh1-EHMT1 and negative control cells into nude mice. A total of 30 days following injection, the mice were sacrificed and the peritoneal nodules were evaluated. As demonstrated in Fig. 4A , increased peritoneal spread was observed in the negative control group compared with that in the BGC-803/sh1-EHMT1 group. Following counting of the nodules, it was evident that there were significantly fewer peritoneal nodules in mice injected with the BGC-803/sh1-EHMT1 cells compared with the number in mice injected with negative control cells (P<0.01; Fig. 4B ). The xenograft model experiment was, therefore, consistent Table I . Association between EHMT1 expression and clinicopathological factors of gastric cancer patients. Positive EHMT1 expression includes all positive cases, including weak and strong staining. EHMT1, euchromatic histone lysine methyltransferase 1; TNM, tumor-node-metastasis.
with the in vitro results, confirming that EHMT1 expression in GC promotes GC metastasis.
EHMT1 promotes GC invasion and metastasis by silencing E-cadherin. E-cadherin is a marker of tumor metastasis, and E-cadherin protein expression was upregulated in BGC-803/sh1-EHMT1 cells compared with that in BGC-803/NC cells (Fig. 4C ). To further verify the effect of EHMT1 on E-cadherin, BGC-803/sh1-EHMT1 and BGC-803/NC cells were subcutaneously injected into BALB/c nude mice. The maximum tumor volume of xenografts derived from the BGC-803/sh1-EHMT1 and BGC-803/NC groups was 0.991 and 0.861 cm 3 , respectively. In addition, the maximum weight of the tumors derived from the BGC-803/sh1-EHMT1 and BGC-803/NC groups was 0.661 and 0.574 g, respectively. IHC suggested that EHMT1 silenced E-cadherin expression in subcutaneous tumors, thus promoting tumor metastasis (Fig. 4D) .
Discussion
Histone modifications, including ubiquitination, phosphorylation, acetylation and methylation serve critical roles in transcriptional repression and activation through the regulation of chromatin structure (15) . EHMT1 has been reported to be upregulated in esophageal squamous cell cancer (12) and breast cancer (13) . However, to the best of our knowledge, the expression level of EHMT1 in GC remains unknown. In the present study, the significant upregulation of EHMT1 in GC was demonstrated using RT-qPCR and IHC, and its expression was associated with lymph node metastasis and tumor stage. It was also demonstrated that EHMT1 promotes the metastasis ability of GC cells and suppresses E-cadherin expression, which may contribute to the existing understanding of GC development.
The transcriptional activity of a gene is often unaffected by DNA methylation, but is determined by chromatinstate (16) . Methylated histones allow close DNA packing and a dense chromatin structure, resulting in a decrease in the transcriptional activity of the gene in question (13) . Fritsch et al established that EHMT1 can methylate the histone and promoter of specific genes, leading to decreased transcriptional activity (17) . EHMT1 serves an important role in the methylation and dimethylation of histone H3 lysine 9 (H3K9) euchromatin, activating a series of downstream reactions and producing corresponding physiological functions. In the majority of cases, EHMT1 will first form a heterodimer with G9a (18) . The G9a/EHMT1 complex can inhibit the expression of p53 by demethylating K373 at the C-terminus of the p53 gene, indicating a promotive effect of EHMT1 in cancer (19) . In the Mage-a tumor stem cell line, H3K9 demethylation (H3K9me2) mediated by the EHMT1/G9a complex has an inhibitory effect on the expression of its antigenic gene (target of tumor vaccine currently undergoing clinical evalutarget of tumor vaccine currently undergoing clinical evaluation world-wide) (20) . The surface antigens of tumor cells are targets of therapeutic drugs (21) , and the EHMT1/G9a complex may function in immune avoidance and therapeutic resistance effects. Epithelial-mesenchymal transition (EMT) refers to the biological process by which epithelial cells are transformed into mesenchymal cells, and is considered to be an important marker of tumor progression. The loss of E-cadherin expression is indicative of the migration and invasion of malignant tumor cells (22) (23) (24) . Previous studies have demonstrated that G9a forms a complex with Snail and binds to the E-cadherin promoter, resulting in H3K9me2 activity and increased potential for EMT and metastasis (25, 26) . Considering that EHMT1 and G9a exist as dimers, the present study investigated whether EHMT1 can affect the expression of E-cadherin. As expected, EHMT1 inhibited the expression of E-cadherin in vitro and in vivo. Thus, EHMT1 may promote the process of GC metastasis by influencing EMT in GC cells.
In conclusion, the present study demonstrated that EHMT1 was highly expressed in GC, and was associated with lymph node metastasis and tumor stage. Depletion of EHMT1 expression inhibited GC cell wound healing, migration and invasion. These results highlight the potential of EHMT1 as a potential therapeutic target for GC.
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